TRCT
MNPR icon

Tower Research Capital (TRC)’s Monopar Therapeutics MNPR Stock Holding History

Tower Research Capital (TRC)’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$31.9K Sell
345
-416
-55% -$25.8K ﹤0.01% 3121
2026
Q1 		$41.7K Buy
761
+414
+119% +$25K ﹤0.01% 2906
2025
Q4 		$22.7K Sell
347
-205
-37% -$16.8K ﹤0.01% 3009
2025
Q3 		$45.1K Buy
+552
New +$24.7K ﹤0.01% 2609
2025
Q2 		– Sell
-303
Closed -$11K – 5453
2025
Q1 		$11K Sell
303
-393
-56% -$14.2K ﹤0.01% 3580
2024
Q4 		$15.3K Buy
+696
New +$11.7K ﹤0.01% 3412
2024
Q3 		– Sell
-1,584
Closed -$5.78K – 5887
2024
Q2 		$5.78K Buy
1,584
+13
+0.8% +$46 ﹤0.01% 4654
2024
Q1 		$5.35K Buy
1,571
+847
+117% +$2.52K ﹤0.01% 4552
2023
Q4 		$1.23K Sell
724
-21
-3% -$43 ﹤0.01% 5413
2023
Q3 		$2.31K Sell
745
-2
-0.3% -$7 ﹤0.01% 5172
2023
Q2 		$3.19K Buy
747
+604
+422% +$3.09K ﹤0.01% 5099
2023
Q1 		$1K Sell
143
-423
-75% -$6.26K ﹤0.01% 5576
2022
Q4 		$7K Sell
566
-60
-10% -$732 ﹤0.01% 4588
2022
Q3 		$5K Buy
626
+152
+32% +$1.44K ﹤0.01% 5154
2022
Q2 		$5K Sell
474
-238
-33% -$2.69K ﹤0.01% 5076
2022
Q1 		$9K Buy
712
+232
+48% +$3.43K ﹤0.01% 4469
2021
Q4 		$8K Buy
+480
New +$10.6K ﹤0.01% 4804
2021
Q2 		– Sell
-442
Closed -$14K – 5697
2021
Q1 		$14K Buy
442
+161
+57% +$5.88K ﹤0.01% 4154
2020
Q4 		$9K Sell
281
-659
-70% -$17K ﹤0.01% 4389
2020
Q3 		$25K Buy
+940
New +$30.4K ﹤0.01% 3791
2020
Q2 		– Sell
-14
Closed – – 4887
2020
Q1 		$0 Buy
+14
New +$877 ﹤0.01% 3564

Other funds holding MNPR

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Tower Research Capital (TRC)'s MNPR Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Monopar Therapeutics (MNPR) stake by 55% in Q2 2026, selling an estimated $25.8K and leaving 345 shares worth $31.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3121.

Tower Research Capital (TRC) first reported a position in MNPR in Q1 2020 and has held it in 21 quarters since. The position peaked at $45.1K in Q3 2025. 95 funds tracked by Wall St. Rank hold MNPR as of Q2 2026.

  • Tower Research Capital (TRC) held 345 shares of Monopar Therapeutics worth $31.9K as of Q2 2026.
  • Tower Research Capital (TRC) sold 416 Monopar Therapeutics shares in Q2 2026, an estimated $25.8K.
  • Monopar Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #3121 holding.
  • Tower Research Capital (TRC) first reported a position in Monopar Therapeutics in Q1 2020 and has held it in 21 quarters since.
  • Tower Research Capital (TRC)'s Monopar Therapeutics position peaked at $45.1K in Q3 2025.
  • 95 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.